VIII. Vacunación

Bibliografía

Referencias

1. Goverment DoHaSCU. Independent report JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021. https://www.gov.uk/ government/publications/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement/jcvi-statement-on-use-of-the-astrazeneca-covid-19-vaccine- 7-april-20212021.
2. Biomedicines P-E-IFIoVa. COVID-19 Vaccine AstraZeneca - Safety Assessment Result: The Vaccine is Safe and Effective in the Fight against COVID-19. https://www.pei.de/EN/newsroom/hp-news/2021/210319- covid-19-vaccine-astrazeneca-safety-assessment-result-vaccine-safe-and-effective.html;jsessionid=CC068EA4C9E7ACAF2604C7A0888EB5FA. intranet212?nn=1641462021.
3. Agency EM. EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further update. https://www.ema.europa.eu/en/news/emas-safety-committee-continues-investigation-covid-19-vaccine-astrazeneca-thromboembolic-events2021.
4. Agency EM. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines) EPITT no:19683. https://www.ema.europa.eu/en/documents/prac-recommendation/ signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf2021.
5. Agency EM. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. https:// www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood2021.
6. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699.
7. BBC. Covid: 30 blood clot cases found in AstraZeneca recipients in the UK. https://www.bbc.com/news/health-566161192021.
8. Agency MHpR. Research and analysis Coronavirus vaccine - weekly summary of Yellow Card reporting. Updated 22 April 2021. UK government. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting2021.
9. Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie. 2021.
10. FDA. Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. The following statement is attributed to Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research and Dr. Anne Schuchat, Principal Deputy Director of the CDC. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine2021.
11. Salud OMdl. The top 10 causes of death. https://www.who.int/news-room/ fact-sheets/detail/the-top-10-causes-of-death2020.
12. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016;118(9):1340-7.
13. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375-7.
14. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study. Stroke. 2016;47(9):2180-2.
15. Maxime Taquet MH, John R Geddes, Sierra Luciano, Paul J Harrison . Universidad de Oxford. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. https:// herstelderepubliek.files.wordpress.com/2021/04/covid-cvt-paper.pdf2021.

Ver Artículo